NRL-1049
NRL-1049 (BA-1049) is a ROCK2 selective inhibitor (IC50: 0.59 µM and 26 µM for ROCK2 and ROCK1 respectively) . NRL-1049 reduces Lysophosphatidic acid induced ROCK activation in endothelial cells. NRL-1049 reduces lesion volume and hemorrhagic transformation in a mouse model of cavernous angiomas. NRL-1049 also preserves the BBB and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice[1].
Product Specifications
CAS Number
[1973494-16-4]
Product Name Alternative
BA-1049 (free base)
UNSPSC
12352005
Target
ROCK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/nrl-1049.html
Purity
99.87
Smiles
C[C@H](C1CCN(CC1)S(=O)(C2=C3C=CN=CC3=CC=C2)=O)N
Molecular Formula
C16H21N3O2S
Molecular Weight
319.42
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ROCK1; ROCK2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MAFA (Transcription Factor MafA, V-maf Musculoaponeurotic Fibrosarcoma Oncogene Family, Protein A (Avian)
Gnl3, CT (Gnl3, Ns, Guanine nucleotide-binding protein-like 3, Nucleolar GTP-binding protein 3, Nucleostemin) (APC) discontinued
Rat Monoclonal Dendritic Cell Marker Antibody (33D1) [DyLight 405]
